Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
ASH 2017 - Chronic Lymphocytic Leukemia
ASH 2017 - Chronic Lymphocytic Leukemia
Acalabrutinib with Obinutuzumab in Relapsed/Refractory and Treatment-Naïve Patients with CLL: The Phase 1b/2 ACE-CL-003 Study
Read More
ASH 2017 - Chronic Lymphocytic Leukemia
Adverse Events, Resource Use, and Economic Burden in Patients with Mantle-Cell Lymphoma in the United States
Read More
ASH 2017 - Chronic Lymphocytic Leukemia
High Complete Response Rates with Pembrolizumab with Rituximab in Patients with Relapsed FL: Results of an Open-Label, Phase 2 Study
Read More
ASH 2017 - Chronic Lymphocytic Leukemia
Efficacy and Safety of Bendamustine and Rituximab as First Salvage Treatment in CLL: Results of the GIMEMA-ERIC LLC1315 Study
Read More
ASH 2017 - Chronic Lymphocytic Leukemia
Phase 1/2 Study of Pembrolizumab in Combination with Ublituximab (TG-1101) and Umbralisib (TGR-1202) in Patients with Relapsed/Refractory CLL
Read More
ASH 2017 - Chronic Lymphocytic Leukemia
Randomized Trial of Ibrutinib versus Ibrutinib plus Rituximab in Patients with CLL
Read More
ASH 2017 - Chronic Lymphocytic Leukemia
Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) for First-Line Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations
Read More
ASH 2017 - Chronic Lymphocytic Leukemia
Combined Venetoclax and Ibrutinib for Patients with Previously Untreated, High-Risk CLL and Relapsed/Refractory CLL: A Phase 2 Trial
Read More
ASH 2017 - Chronic Lymphocytic Leukemia
A Multicenter, Phase 2 Study of Ibrutinib plus FCR as Frontline Therapy for Younger Patients with CLL
Read More
ASH 2017 - Chronic Lymphocytic Leukemia
Initial Results of the Phase 2 Treatment-Naïve Cohort in a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in CLL
Read More
1
2
Page 1 of 2
Results 1 - 10 of 20